Skip to search formSkip to main contentSkip to account menu

mirodenafil

Known as: 5-ethyl-2-(5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one, 5-ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Phosphodiesterase 5 inhibitorPyrimidinonesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials
Abstract Aim: To systematically review evidence on the efficacy and safety of mirodenafil treatment in erectile dysfunction (ED… 
2014
2014
The Efficacy of Mirodenafil for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Middle-Aged Males
Purpose The aim of this study was to investigate the efficacy of mirodenafil in middle-aged male patients with chronic… 
2013
2013
Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study
We evaluated the clinical efficacy and safety of the coadministration of a PDE5 inhibitor and an α-adrenergic blocker in patients… 
Review
2012
Review
2012
Looking to the Future for Erectile Dysfunction Therapies
The treatment of erectile dysfunction (ED) has been revolutionized during the last 2 decades with several treatment options now… 
2011
2011
Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells.
In this study, we investigated the effects of a combination of Ginkgo biloba extracts (GBE) and phosphodiesterase type 5 (PDE-5… 
2010
2010
Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats
The area under the curve (AUC) of mirodenafil after intravenous administration in diabetes mellitus induced by streptozotocin… 
2010
2010
The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury
Impotence is one of the common complications after the radical prostatectomy. One of the main reasons of this complication is due… 
2010
2010
Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541.
PURPOSE This study was performed to find which types of hepatic CYP isoforms are responsible for the metabolism of mirodenafil (a… 
2009
2009
Dose‐dependent pharmacokinetics and first‐pass effects of mirodenafil, a new erectogenic, in rats
The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and… 
2007
2007
Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats
AbstractAim:To investigate the pharmacokinetic profile and tissue distribution of a novel phosphodiesterase type 5 inhibitor, 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)